Shares of Cepheid (NASDAQ:CPHD) dropped 2.3% during mid-day trading on Tuesday . The stock traded as low as $34.01 and last traded at $34.26, with a volume of 275,606 shares traded. The stock had previously closed at $35.07.

CPHD has been the topic of several research analyst reports. Jefferies Group raised their price target on shares of Cepheid from $28.00 to $34.00 and gave the stock a “hold” rating in a research report on Wednesday, August 17th. Morgan Stanley initiated coverage on shares of Cepheid in a research report on Wednesday, June 15th. They issued an “equal weight” rating and a $30.00 price target on the stock. Zacks Investment Research upgraded shares of Cepheid from a “hold” rating to a “strong-buy” rating and set a $41.00 price target on the stock in a research report on Monday, August 1st. JPMorgan Chase & Co. raised their price target on shares of Cepheid from $32.00 to $35.00 and gave the stock a “neutral” rating in a research report on Friday, July 29th. Finally, TheStreet lowered shares of Cepheid from a “hold” rating to a “sell” rating in a research report on Monday, June 6th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Cepheid currently has an average rating of “Buy” and a consensus price target of $40.13.

The stock’s 50-day moving average price is $34.79 and its 200 day moving average price is $31.79. The stock’s market capitalization is $2.53 billion.

Cepheid (NASDAQ:CPHD) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.19. The firm had revenue of $146 million for the quarter, compared to analyst estimates of $145.82 million. During the same quarter in the previous year, the company earned ($0.06) earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. On average, equities analysts forecast that Cepheid will post $0.33 EPS for the current year.

In other Cepheid news, VP Scott A. Campbell sold 746 shares of the stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $36.71, for a total transaction of $27,385.66. Following the sale, the vice president now directly owns 10,721 shares in the company, valued at $393,567.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.